Core Viewpoint - 微脉公司 has submitted an application for listing on the Hong Kong Stock Exchange, aiming to leverage its position as a leader in AI-enabled full-cycle management services in healthcare [1][3]. Company Overview - 微脉 is recognized as a pioneer and leader in AI full-cycle management services in China, focusing on connecting hospitals, doctors, and patients to reconstruct the healthcare service value chain [3]. - The company is one of the top three full-cycle management service providers in China by revenue as of 2024 and the largest patient-oriented AI-enabled service provider [3]. Market Potential - The full-cycle management service market in China is projected to grow from RMB 16.3 billion in 2020 to RMB 61.4 billion by 2024, with a compound annual growth rate (CAGR) of 39.3%. By 2030, the market is expected to reach RMB 365.4 billion, indicating a CAGR of 34.6% from 2024 to 2030 [4]. Financial Performance - For the fiscal years 2022, 2023, and 2024, 微脉 reported revenues of approximately RMB 5.12 billion, RMB 6.28 billion, and RMB 6.53 billion, respectively. The corresponding losses were approximately RMB 4.14 billion, RMB 1.50 billion, and RMB 1.93 billion [4][6]. - The gross profit margins for the same years were 17.2%, 18.9%, and 19.9%, respectively, indicating a gradual improvement in profitability [6].
新股消息 | 微脉再度递表港交所 为中国前三大全病程管理服务提供商
智通财经网·2025-07-02 22:47